<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1501">
  <stage>Registered</stage>
  <submitdate>15/03/2007</submitdate>
  <approvaldate>15/03/2007</approvaldate>
  <nctid>NCT00448214</nctid>
  <trial_identification>
    <studytitle>Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</studytitle>
    <scientifictitle>Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>150-CL-030</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - YM150
Treatment: drugs - warfarin

Experimental: 1 - Low dose

Experimental: 2 - Middle dose

Experimental: 3 - High dose

Active Comparator: 4 - 


Treatment: drugs: YM150
Oral

Treatment: drugs: warfarin
Oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All clinically relevant bleeds during the treatment period rated as "major" or "clinically relevant non-major(CRNM)"</outcome>
      <timepoint>16 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of symptomatic stroke</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of transient ischemic attack (TIA)</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of systemic thromboembolic event</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of the bleeding rates</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other safety assessments</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK, PD variables</outcome>
      <timepoint>16 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects are eligible for the study if all of the following apply:

          -  Subject has paroxysmal permanent or persistent NVAF

          -  Subject has INR of 2.0 or below and an aPTT = 1.5 times the upper limit of normal at
             the baseline visit.

          -  Legal minimum age requirement (country-specific).

          -  Written informed consent has been obtained.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of heart valve disorders

          -  History of rheumatic fever.

          -  History of stroke and/or systemic embolism (including TIA).

          -  History of Acute Coronary Syndrome (ACS).

          -  Indication for warfarin other than NVAF.

          -  Known hemorrhagic disorder and/or coagulation disorder.

          -  Active bleeding or any condition associated with increased risk of bleeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>448</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Launceston</hospital>
    <postcode> - Launceston</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Pok Fu Lam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Sha Tin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kansai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyusyu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shikoku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tohoku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hastings</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Nakhon Ratchasima</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial
      fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics
      (anti-thrombotic potential) in the target population</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00448214</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Central Contact</name>
      <address>Astellas Pharma Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>